Search Tag: SARS-CoV-2

Executive Health Management

J&J’s Vaccine Trial Paused

2020 13 Oct

Johnson & Johnson has announced temporarily pausing the COVID-19 vaccine candidate trials due to an unexplained illness in a study participant.   You might also like: Rushing COVID-19 Vaccine Development: Is It Justified?   As reported by STAT News, the company has informed external researchers through a document that a “passing... Read more

Executive Health Management

How Exposure to SARS-CoV-2 Varies Across Hospital Settings

2020 24 Sep

New research from the UK has detected SARS-CoV-2 seroconversion among asymptomatic healthcare workers. Moreover, researchers were able to identify variation in the occupational risk of exposure to the pathogen – which causes COVID-19 – between hospital departments.   You might also like: COVID-19: Risk Factors for Healthcare Workers... Read more

Executive Health Management

Siemens Healthineers Collaboration With CDC To Standardize SARS-CoV-2 Assays

2020 15 Sep

The collaboration will standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization that could one day be extrapolated to thresholds considered sufficient to confer immunity. Standardization across manufacturers is also expected to improve patient care by enabling long-term antibody level... Read more

Executive Health Management

Siemens Healthineers Collaboration With CDC To Standardize SARS-CoV-2 Assays

2020 15 Sep

The collaboration will standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization that could one day be extrapolated to thresholds considered sufficient to confer immunity. Standardization across manufacturers is also expected to improve patient care by enabling long-term antibody level... Read more

Executive Health Management

New Sample Pooling Method for COVID-19 Testing

2020 06 Aug

Widespread testing for COVID-19 derives important epidemiological data that can inform strategies on disease monitoring and control. However, shortages of test kits and bottlenecks in processing of results prevent many countries from implementing mass testing. This leaves many patients (especially those not showing symptoms) untested, increasing... Read more

Executive Health Management

Witty to Help WHO with COVID-19 Vaccine Development

2020 20 Apr

Sir Andrew Witty, president of UnitedHealth Group and CEO of Optum and f ormer GlaxoSmithKline (GSK) chief executive , has taken a leave of absence from his current job to join the World Health Organization (WHO) in the agency’s efforts to develop a COVID-19 vaccine.   You may also like: Where Does COVID-19 Vaccine Development Stand?... Read more

Executive Health Management

COVID-19 Experience of Italian GPs

2020 16 Apr

A new study published in the Annals of Internal Medicine assesses challenges faced by general practitioners (GPs) in the prevention and management of COVID-19 in Lombardy, Italy.   You may also like : COVID-19 Pandemic: Lessons from Italy   As of 8 April, Italy was the most COVID-19-affected country in Europe. Of 135 000... Read more

Executive Health Management

COVID-19: in Search for Answers to Major Questions

2020 16 Apr

Researchers use mathematical modelling to predict the persistence of SARS-CoV-2 in the human population after its initial pandemic stage and compute a more realistic picture of the coronavirus infection rate .   You may also like : Where Does COVID-19 Vaccine Development Stand?   Five-Year Projection One study (... Read more

Executive Health Management

Where Does COVID-19 Vaccine Development Stand?

2020 11 Apr

Researchers around the world are testing a wide range of COVID-19 vaccine candidates, with over a hundred vaccines in development, and almost 600 clinical trials either ongoing or completed.   You may also like : Teaming and Funding Opportunities for COVID-19 Researchers   The Coalition for Epidemic Preparedness Innovations (CEPI),... Read more

Executive Health Management

Warnings about Potential Treatments for COVID-19

2020 09 Apr

An early-released review warns about potentially serious adverse events for chloroquine, hydroxychloroquine and azithromycin when used to treat and prevent COVID-19 . It comes only days after the U.S. Centers for Disease Control and Prevention (CDC) had removed guidelines for using hydroxychloroquine as a potential treatment.  ... Read more